Precigen (PGEN) Cash from Investing Activities (2012 - 2026)
Precigen's (PGEN) quarterly Cash from Investing Activities came in at $21.0 million in Q1 2026, up 424.72% year-on-year from $4.0 million in Q1 2025, and down 47.41% on a QoQ basis from $39.9 million in Q4 2025.
Precigen (PGEN) Cash from Investing Activities (2012 - 2026) Analysis & Trends
Precigen (PGEN) has 15 years of Cash from Investing Activities data on file, last reported at $21.0 million in Q1 2026.
- On a quarterly basis, Cash from Investing Activities rose 424.72% year-over-year to $21.0 million in Q1 2026; TTM through Mar 2026 was $25.9 million, a 150.55% increase from a year earlier, with the FY2025 full-year figure at -$1.5 million, up 92.59% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at $21.0 million, down from $39.9 million in the prior quarter.
- Over the last five years, Cash from Investing Activities for PGEN reached as high as $181.9 million in Q3 2022 and fell as low as -$65.4 million in Q4 2024.
- Historically, Cash from Investing Activities has averaged $13.1 million across 5 years, with a median of $15.0 million in 2024.
- Across the five-year window, Cash from Investing Activities surged 726.13% in 2022 and plunged 1221.28% in 2025, its largest moves.
- Year by year, Cash from Investing Activities stood at $11.4 million in 2022, then increased by 16.39% to $13.3 million in 2023, then plunged by 591.74% to -$65.4 million in 2024, then jumped by 160.99% to $39.9 million in 2025, then slumped by 47.41% to $21.0 million in 2026.
- Per Business Quant data, the three most recent Cash from Investing Activities figures were $21.0 million in Q1 2026, $39.9 million in Q4 2025, and -$63.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 172.62 Mn |
| 10 | Precigen | 1.95 Bn | 1.95 Bn | 20.69 Mn | 20.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20.97 Mn |
| Mar 31, 2026 | 20.97 Mn |
| Dec 31, 2025 | 39.87 Mn |
| Dec 31, 2025 | 39.87 Mn |
| Sep 30, 2025 | -63.39 Mn |
| Sep 30, 2025 | -63.39 Mn |
| Jun 30, 2025 | 28.44 Mn |
| Jun 30, 2025 | 28.44 Mn |
| Mar 31, 2025 | -6.46 Mn |
| Mar 31, 2025 | -6.46 Mn |
| Dec 31, 2024 | -65.37 Mn |
| Dec 31, 2024 | -65.37 Mn |
| Sep 30, 2024 | 5.65 Mn |
| Sep 30, 2024 | 5.65 Mn |
| Jun 30, 2024 | 14.96 Mn |
| Jun 30, 2024 | 14.96 Mn |
| Mar 31, 2024 | 24.05 Mn |
| Mar 31, 2024 | 24.05 Mn |
| Dec 31, 2023 | 13.29 Mn |
| Dec 31, 2023 | 13.29 Mn |